Context Therapeutics amends Integral license for CTIM-76 after finding potential third-party patent conflict

Context Therapeutics Inc.

Discovered third-party patents expiring Jan 2034 may cover CTIM-76; company believes it has defenses but may not prevail.
Amendment reduces development milestones from $55M to $15M, sales milestones from $130M to $12.5M.
Royalty reduced from 8–12% to flat 6% on net sales, starting no sooner than February 2034.
License narrowed to only CTIM-76; company no longer obligated to reimburse Integral for research funding.
Deal includes mutual releases and revised milestone triggers tied to Phase 1b/2, Phase 3, and marketing approvals.

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Context Therapeutics Inc. amended Integral License Agreement with Integral Molecular, Inc. (effective 2024-02-29).

Action: amendment
Agreement: collaboration
Counterparty: Integral Molecular, Inc.
Effective: 2024-02-29

Exact text from the filing

Context Therapeutics Inc. (the “Company”) amended its collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”)

View on SEC.gov

246 material agreements filed in the last 30 days. Browse all material agreements →

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.